China's drug regulator included Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) subsidiary Suzhou Shengdia Biopharmaceutical's ruzaltatug rezetecan drug for non-small cell lung cancer in its breakthrough therapy designation list, according to a Saturday filing with the Shanghai bourse.
The drug is indicated for combination with bevacizumab to treat advanced or metastatic non-squamous non-small cell lung cancer with epidermal growth factor receptor tyrosine kinase inhibitors, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments